Trial Profile
A phase I/II trial of rituxan [rituximab] and BEAM [carmustine + cytarabine + etoposide + melphalan] high-dose chemotherapy and autologous peripheral blood progenitor transplant for indolent lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Carmustine (Primary) ; Cytarabine (Primary) ; Etoposide (Primary) ; Melphalan (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- 01 Sep 2011 Actual end date Sep 2009 added as reported by ClinicalTrials.gov.
- 01 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jan 2008 New trial record.